PRT-1419 is under clinical development by Prelude Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRT-1419’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRT-1419 is under development for the treatment of solid tumors, sarcoma, melanoma, small cell lung cancer, non-small cell lung cancer, DLBCL, triple negative breast cancer, relapsed and refractory hematologic malignancies including multiple myeloma (MM), t-cell lymphomas, chronic myelomonocytic leukemia (CMML), non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), chronic lymphocytic leukemia, B-cell non-hodgkin lymphoma (NHL) including follicular lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma, myeloproliferative neoplasm overlap syndrome and high-risk myelodysplastic syndrome (MDS). The drug candidate is administered by oral route and intravenous route of administration. It acts by targeting MCL1.
Prelude Therapeutics overview
Prelude Therapeutics (Prelude) is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The company product pipeline includes PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor and PRT3645, a next-generation CDK4/6 inhibitor. Prelude others pipeline includes PRT3789 a first-in-class SMARCA2/BRM protein degraded. It also carries out clinical trials. The company serves throughout the US . Prelude is headquartered in Wilmington, Delaware, the United States.
For a complete picture of PRT-1419’s drug-specific PTSR and LoA scores, buy the report here.